A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Safety and Efficacy of Antroquinonol in Hospitalized Patients With Mild to Moderate Pneumonia Due to COVID-19

Cheng et al., NCT04523181, NCT04523181, Dec 2021

Source

PDF

All
Studies

Meta
Analysis

https://c19early.org/cheng7.html

RCT 124 hospitalized COVID-19 patients showing no significant differences with antroquinonol.

Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments1. Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.

Important missing comments or errors? Let us know.

risk of progression, 200.0% higher, RR 3.00, p = 1.00, treatment 1 of 62 (1.6%), control 0 of 62 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), respiratory failure.

recovery time, 16.7% higher, relative time 1.17, p = 0.72, treatment mean 7.0 (±20.1) n=62, control mean 6.0 (±8.03) n=62, time to 2 point improvement.

recovery time, 6.5% lower, relative time 0.94, p = 0.52, treatment mean 29.0 (±2.01) n=62, control mean 31.0 (±24.1) n=62, time to zero.

hospitalization time, 1.5% lower, relative time 0.98, p = 0.92, treatment mean 6.4 (±5.38) n=60, control mean 6.5 (±5.54) n=62.

time to viral-, 6.7% lower, relative time 0.93, p = 0.87, treatment mean 14.0 (±18.1) n=62, control mean 15.0 (±44.2) n=62.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

1. c19early.org, c19early.org/soc/usa.html.

Cheng et al., 23 Dec 2021, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, trial NCT04523181 (history). Contact: howard@goldenbiotech.com.

This Paper Antroquinonol All

Late treatment
is less effective

Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0